Novo Nordisk's AI Leap: Supercomputers & Cardiometabolic Breakthroughs - Life AI Weekly #22

Hi there,

Welcome to this week's edition of Life AI Weekly, where we delve into the latest advancements in Healthcare and Life Sciences AI. This week, we highlight significant partnerships and innovations that are shaping the future of medical technology. Novo Nordisk has teamed up with DCAI to leverage an AI supercomputer, aiming to accelerate drug discovery processes. Meanwhile, Deep Apple Therapeutics has also partnered with Novo Nordisk to explore new therapeutic avenues.

In other news, Unlearn is utilizing AI digital twins to enhance clinical trials, potentially revolutionizing how new treatments are tested. Additionally, Deep LS GmbH and TU Darmstadt have secured funding to further their AI drug development initiatives. Stay tuned as we continue to bring you the latest updates in the intersection of AI and healthcare.

Lyrebird Health has raised $12 million to enhance its AI-powered healthcare transcription platform and expand internationally. Leumas secured $2.2 million to develop robot factories for the pharmaceutical sector. Lembas announced a breakthrough in GLP-1 activation for weight management and secured $3.6 million to scale its solution.

Novo Nordisk has entered a multiyear agreement with DCAI to use the Gefion AI Supercomputer to enhance drug discovery and healthcare innovation. Deep Apple Therapeutics has announced a collaboration with Novo Nordisk to develop oral therapeutics for cardiometabolic diseases using AI-driven drug discovery. AI-powered digital twins by Unlearn are transforming clinical trials by reducing participant numbers and accelerating drug development, particularly for ALS and Alzheimer's treatments. Deep LS GmbH and the Technical University of Darmstadt have been awarded 338,300 Euros from the LOEWE program for their AI-supported drug development project, focusing on the protein FKBP51.

AllSci has received a grant from Montgomery County's Technology Innovation Fund to enhance its AI platform for pharmaceutical and biotech research. Lenovo announced it will supply a high-performance computing system to the IEO Monzino Group to boost research in oncology and cardiology using AI.

GenBio AI has announced Dr. Emma Lundberg as Co-Founder and Chief Scientific Advisor. She will lead the company's data strategy and scientific initiatives for developing an AI-driven digital organism.

GLOBO Language Solutions has launched its AI interpreter, GLOBO KAI™, to 3,000 U.S. healthcare providers. Guy’s and St Thomas’ NHS Foundation Trust initiated the PATH program with partners like NVIDIA to enhance healthcare delivery using AI. Ellipsis Health introduced Sage, an AI Care Manager, backed by $45 million from investors including Salesforce.